Compounds not yet covered
Compounds not yet covered: 7 articles from Peptides Facts. Evidence-led reference on research peptides.
ARA-290: The Innate Repair Receptor and Phase 2 Data
An eleven-residue peptide cut from the structure of erythropoietin was designed to engage a tissue-protective receptor and skip the blood-forming one. Its human record is two small trials in one disease, with a nerve-imaging surrogate as the primary endpoint.
Kisspeptin-10 and KISS1R: Potency and Half-Life
The ten-residue C-terminal fragment binds the receptor about as well as the fifty-four-residue parent. In rodents it does not behave that way, and the resolution turns out to be only partly pharmacokinetic.
Dihexa: The HGF/c-Met Claim and the Distance Between a Rodent Model and a Person
Dihexa is a modified angiotensin IV fragment claimed to potentiate hepatocyte growth factor signalling in the brain. The paper that made that claim was retracted in 2025, there are no human data, and the pathway it targets is a proto-oncogene.
DSIP: A 1977 Discovery With a Thin and Contradictory Evidence Record
Delta sleep-inducing peptide was isolated from rabbit blood almost fifty years ago. No gene, precursor or receptor has been found for it, and its small human trials disagree with each other.
PEG-MGF: What Mechano Growth Factor Is, and What PEGylating a Fragment Changes
Mechano growth factor names a splice variant of the IGF-1 gene. The peptide sold as PEG-MGF is a synthetic fragment of it with a polymer attached. Whether the fragment exists naturally is disputed, a pharmaceutical group could not reproduce its core effect, and the PEGylated form has no published studies of its own.
Semax: An ACTH(4–7) Fragment, BDNF, and What the Russian Literature Does and Does Not Show
Semax is a hormone fragment with the hormone's endocrine activity engineered out. Its proposed mechanism runs through brain-derived neurotrophic factor, the evidence for that is rodent work from one programme, and the human data are stroke studies that cannot be appraised to current standards from outside.
VIP: A 28-Residue Neuropeptide With Receptors Almost Everywhere
Vasoactive intestinal peptide was isolated from pig intestine in 1970 and turned out to act on blood vessels, glands, immune cells and the brain's master clock. That reach is why it has been so hard to make into a drug.